Valacyclovir

CHEMBL1349 Phase 4 Đã phê duyệt Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
324.3 g/mol
LogP
-0.9
Phase
4

This antiviral medication is a prodrug that is converted in the body into acyclovir, used to treat infections caused by herpes viruses including genital herpes, cold sores, shingles (herpes zoster), and chickenpox. It works by blocking the viral enzyme needed for the herpes virus to copy its DNA and reproduce. When taken daily as suppressive therapy, it can significantly reduce the frequency and severity of herpes outbreaks and lower the risk of transmitting the virus to others.

Khối lượng phân tử

324,3400 g/mol

LogP

-0,90

TPSA

147,00 Ų

Lipinski RO5

Đạt

Lĩnh vực điều trị

Cơ chế tác dụng

Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Cơ chế

Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.

Cấu trúc 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CC(C)[C@H](N)C(=O)OCCOCn1cnc2c(=O)nc(N)[nH]c21

InChI

InChI=1S/C13H20N6O4/c1-7(2)8(14)12(21)23-4-3-22-6-19-5-16-9-10(19)17-13(15)18-11(9)20/h5,7-8H,3-4,6,14H2,1-2H3,(H3,15,17,18,20)/t8-/m0/s1

Molecular Formula

C13H20N6O4

HBD / HBA

3 / 7

Liên kết có thể quay

8

Nguyên tử nặng

23

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Câu hỏi thường gặp

This antiviral medication is a prodrug that is converted in the body into acyclovir, used to treat infections caused by herpes viruses including genital herpes, cold sores, shingles (herpes zoster), and chickenpox. It works by blocking the viral enzyme needed for the herpes virus to copy its DNA and reproduce. When taken daily as suppressive therapy, it can significantly reduce the frequency and severity of herpes outbreaks and lower the risk of transmitting the virus to others.

Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.

Yes, Valacyclovir is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1349. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 135398742. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

Tuyên bố miễn trách y tế

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.